secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001213900-24-019249
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics reports FY2023 net loss of $64.5M; cash runway through Q3 2025 on $50M Feb 2024 offering
--------------------------------------------------------------------------------

- Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).
- Cash and equivalents $86.9M at Dec 31, 2023; Feb 2024 $50M offering extends runway through Q3 2025.
- BEACON Phase 1b/2a in CSU enrolling; initial data from first four cohorts expected Q3 2024.
- SPOTLIGHT Phase 1b/2a in CIndU approved; data expected H2 2024.
- Phase 1 trial in LR-MDS initiated; initial data anticipated mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/0001213900-24-019249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/ea0201079-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-019249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer